Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LUMO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Quote Panel
Key Metrics
Relative Strength
LUMO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
After-hours 0.00$
-4.34 (-100.00%)
Relative Strenght
84
Volume Buzz
280%
Earning Acce
Yes
Dist 52w H.
5%
globenewswire.com
14 hours ago
prnewswire.com
15 hours ago
prnewswire.com
15 hours ago
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.98
vsĀ -0.68
Q1.23
N/A
-0.89
vsĀ -0.92
Q2.23
N/A
-1.09
vsĀ -0.94
Q3.23
N/A
-1.04
vsĀ -0.86
Q4.23
N/A
-1.17
vsĀ -0.98
Q1.24
N/A
-1.29
vsĀ -0.89
Q2.24
N/A
-0.93
vsĀ -1.09
Q3.24
N/A
-0.90
vsĀ -1.04
Q4.24
N/A
-0.67
vsĀ -1.17
Q1.25
N/A
-0.38
vsĀ -1.29
Sales Growth
YoY
Current
Estimates
Q4.22
+133%
512KĀ vsĀ 220K
Q1.23
+523%
691KĀ vsĀ 111K
Q2.23
+31%
527KĀ vsĀ 403K
Q3.23
-99%
7KĀ vsĀ 497K
Q4.23
+61%
826KĀ vsĀ 512K
Q1.24
-76%
165KĀ vsĀ 691K
Q2.24
-7%
488KĀ vsĀ 527K
Q3.24
+10271%
726KĀ vsĀ 7K
Q4.24
-46%
443.3KĀ vsĀ 826K
Q1.25
-9%
150KĀ vsĀ 165K
Return on Equity
QoQ
Q2.22
-10%
-0.10
vsĀ -0.09
Q3.22
-11%
-0.11
vsĀ -0.10
Q4.22
-13%
-0.13
vsĀ -0.11
Q1.23
-13%
-0.13
vsĀ -0.13
Q2.23
-20%
-0.20
vsĀ -0.13
Q3.23
-23%
-0.23
vsĀ -0.20
Q4.23
-35%
-0.35
vsĀ -0.23
Q1.24
-60%
-0.60
vsĀ -0.35
Q2.24
-73%
-0.73
vsĀ -0.60
Q3.24
-152%
-1.52
vsĀ -0.73
Institutionnal Ownership
QoQ
Q3.22
33
33
vsĀ 35
-6%
Q4.22
37
37
vsĀ 33
12%
Q1.23
34
34
vsĀ 37
-8%
Q2.23
34
34
vsĀ 34
NA
Q3.23
33
33
vsĀ 34
-3%
Q4.23
37
37
vsĀ 33
12%
Q1.24
35
35
vsĀ 37
-5%
Q2.24
35
35
vsĀ 35
NA
Q3.24
28
28
vsĀ 35
-20%
Q4.24
1
1
vsĀ 28
-96%
Forecast
93%2025-Revenue
-112%2025-EPS
82%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
H.C. Wainwright
downgradePrevious: Not converted
2024-10-24
Now: Neutral
EF Hutton
initialisePrevious: Not converted
2024-09-24
Now: Buy
Jefferies
downgradePrevious: Not converted
2022-11-14
Now: Hold
